86 results on '"Octreotide scintigraphy"'
Search Results
2. Thymic pathologies in myasthenia gravis: a preoperative assessment of CAT scan and nuclear based imaging.
- Author
-
Jordan, Berit, Kellner, Juliane, Jordan, Karin, Bähre, Manfred, Behrmann, Curd, and Zierz, Stephan
- Subjects
- *
THYMUS diseases , *THYMOMA , *MYASTHENIA gravis , *HYPERPLASIA , *THYMECTOMY - Abstract
Precise diagnostic work up of a suspected thymic pathology in patients with myasthenia gravis (MG) is very important for potential surgical implications and further disease course. In this study the diagnostic value of combined preoperative radiological (CAT scan) and nuclear based imaging (octreotide and thallium scintigraphy) in patients with MG was evaluated. Twenty four patients were included. Histopathology revealed thymoma in nine patients, thymic carcinoma (TC) in one patient, lymphofollicular hyperplasia in seven patients, and involuted thymus in another seven patients. Diagnostic sensitivity for detecting thymoma/TC was 80 % in CAT scan as well as in somatostatin scintigraphy; the combination of both procedures reached 90 %. However, the diagnostic specifity to exclude thymoma in CAT scan was 100 % and in octreotide scintigraphy 85.7 %. Semiquantitative octreotide uptake significantly correlated with histological grading of thymoma/TC ( r = 0.764) and histological proliferation rate Ki67 ( r = 0.894). Thallium scintigraphy was positive only in one out of four thymoma cases. In this study, somatostatin scintigraphy has been shown to be a useful additional diagnostic technique in detecting thymic malignancies in patients with MG. These results might be especially helpful in patients with late onset MG as these patients are in general no candidates for thymectomy. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
3. 68Ga DOTA-TATE PET/CT allows tumor localization in patients with tumor-induced osteomalacia but negative 111In-octreotide SPECT/CT.
- Author
-
Breer, Stefan, Brunkhorst, Thomas, Beil, F. Timo, Peldschus, Kersten, Heiland, Max, Klutmann, Susanne, Barvencik, Florian, Zustin, Jozef, Gratz, Klaus-Friedrich, and Amling, Michael
- Subjects
- *
BONE tumors , *OSTEOMALACIA , *BIOMINERALIZATION , *OCTREOTIDE acetate , *PARANEOPLASTIC syndromes , *HYPOPHOSPHATEMIA , *STRESS fractures (Orthopedics) - Abstract
Abstract: Tumor-induced osteomalacia (TIO) is a paraneoplastic syndrome characterized by renal phosphate wasting, hypophosphatemia and low calcitriol levels as well as clinical symptoms like diffuse bone and muscle pain, fatigue fractures or increased fracture risk. Conventional imaging methods, however, often fail to detect the small tumors. Lately, tumor localization clearly improved by somatostatin-receptor (SSTR) imaging, such as octreotide scintigraphy or octreotide SPECT/CT. However, recent studies revealed that still a large number of tumors remained undetected by octreotide imaging. Hence, studies focused on different SSTR imaging methods such as 68Ga DOTA-NOC, 68Ga DOTA-TOC and 68Ga DOTA-TATE PET/CT with promising first results. Studies comparing different SSTR imaging methods for tumor localization in TIO are rare and thus little is known about diagnostic alternatives once a particular method failed to detect a tumor in patients with TIO. Here, we report the data of 5 consecutive patients suffering from TIO, who underwent both 111Indium-octreotide scintigraphy (111In-OCT) SPECT/CT as well as 68Ga DOTA-TATE PET/CT for tumor detection. While 111In-OCT SPECT/CT allowed tumor detection in only 1 of 5 patients, 68Ga DOTA-TATE PET/CT was able to localize the tumor in all patients. Afterwards, anatomical imaging of the region of interest was performed with CT and MRI. Thus, successful surgical resection of the tumor was achieved in all patients. Serum phosphate levels returned to normal and all patients reported relief of symptoms within weeks. Moreover, an iliac crest biopsy was obtained from every patient and revealed marked osteomalacia in all cases. Follow-up DXA revealed an increase in BMD of up to 34.5% 1-year postoperative, indicating remineralization. No recurrence was observed. In conclusion our data indicates that 68Ga DOTA-TATE PET/CT is an effective and promising diagnostic tool in the diagnosis of TIO, even in patients in whom 111In-OCT prior failed to detect a tumor. [Copyright &y& Elsevier]
- Published
- 2014
- Full Text
- View/download PDF
4. Tumor-Induced Osteomalacia and the Importance of Plasma Fibroblast Growth Factor 23 as an Indicator: Diagnostic Delay Leads to a Suicide Attempt
- Author
-
Azeem Mohammed, Nardos Belayneh, La Rae Seemann, and Sandeep A. Padala
- Subjects
Fibroblast growth factor 23 ,Delayed Diagnosis ,Fibromyalgia ,Hypophosphatemia ,Paraneoplastic Syndromes ,Epidemiology ,Octreotide ,Parathyroid hormone ,Suicide, Attempted ,Case Report ,Gastroenterology ,0302 clinical medicine ,FGF23 ,phosphaturic mesenchymal tumor ,Safety, Risk, Reliability and Quality ,Neoplasms, Connective Tissue ,Osteomalacia ,lcsh:R5-920 ,Middle Aged ,Magnetic Resonance Imaging ,Phosphaturic mesenchymal tumor ,030220 oncology & carcinogenesis ,Female ,medicine.symptom ,lcsh:Medicine (General) ,Safety Research ,medicine.drug ,lcsh:RB1-214 ,medicine.medical_specialty ,Pain ,030209 endocrinology & metabolism ,osteomalacia ,Phosphates ,fibroblast growth factor 23 ,03 medical and health sciences ,octreotide scintigraphy ,Internal medicine ,medicine ,lcsh:Pathology ,Humans ,renal phosphate wasting ,Radionuclide Imaging ,Bone pain ,tumor-induced osteomalacia ,business.industry ,medicine.disease ,Rickets, Hypophosphatemic ,Fibroblast Growth Factors ,Fibroblast Growth Factor-23 ,Hypophosphatemic Rickets ,business - Abstract
Tumor-induced osteomalacia is a rare hypophosphatemic disease caused by unregulated production of fibroblast growth factor 23 by a tumor, thereby inducing renal phosphate wasting and inhibiting appropriate increase of calcitriol production. Symptoms of tumor-induced osteomalacia, including muscle weakness, bone pain, and pathologic fractures, are nonspecific and warrant further workup. We report the case of a 50-year-old African American female with no known psychiatric illness who was admitted after a failed suicide attempt provoked by severe bone pain. She had been treated for fibromyalgia and hypophosphatemic rickets at other facilities with no improvement. The findings of profound renal phosphate wasting initiated further evaluation, which revealed an elevated fibroblast growth factor 23 level and a right proximal fibular mesenchymal tumor on octreotide scintigraphy. Magnetic resonance imaging confirmed the findings of a solid intramuscular tumor corresponding to the octreotide avid lesion. After wide excision of the tumor, serum phosphate and parathyroid hormone levels began to normalize. This case highlights the importance of extensively investigating the cause of bone pain, weakness, and fatigue in patients without a family history of hypophosphatemia or bone disorders. The aforementioned symptoms may precede recurrent pathological fractures, and a thorough workup ensures that a diagnosis of tumor is not delayed or overlooked, as tumor resection confers a favorable prognosis and dramatic increase in the quality of life for patients.
- Published
- 2019
5. Differential Diagnosis of a Hepatic Mass by 99mTc-labelled Red Cells and Octreotide Scintigraphy
- Author
-
Ignacio León-Asuero-Moreno, María Cinta Calvo-Morón, Francisco Javier García-Gómez, Juan Castro-Montaño, and Gertrudis Sabatel-Hernández
- Subjects
medicine.medical_specialty ,business.industry ,Hepatic mass ,General Engineering ,chemistry.chemical_element ,Octreotide ,Technetium ,medicine.disease ,Gastroenterology ,chemistry ,Internal medicine ,Octreotide scintigraphy ,Carcinoma ,medicine ,Differential diagnosis ,business ,medicine.drug - Published
- 2019
6. Das Karzinoid des Mittelohrs.
- Author
-
Rieh, E., Steigerwald, C., Göbel, H., Maier, W., and Offergeld, C.
- Abstract
Copyright of HNO is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2009
- Full Text
- View/download PDF
7. 99Tcm-octreotide scintigraphy and serum eye muscle antibodies in evaluation of active thyroid-associated ophthalmopathy
- Author
-
C Dong, Y Zhang, B Sun, Shengtao Li, Z Zhang, and Chun-Xia Yan
- Subjects
medicine.medical_specialty ,genetic structures ,medicine.medical_treatment ,Glaucoma ,030209 endocrinology & metabolism ,Eye muscle ,medicine.disease_cause ,Gastroenterology ,Autoimmunity ,Neuro-ophthalmology ,03 medical and health sciences ,0302 clinical medicine ,Ophthalmology ,Internal medicine ,Octreotide scintigraphy ,medicine ,Thyroid-Associated Ophthalmopathy ,biology ,business.industry ,Immunosuppression ,medicine.disease ,eye diseases ,Clinical Study ,030221 ophthalmology & optometry ,biology.protein ,Antibody ,business - Abstract
99 Tc m -octreotide scintigraphy and serum eye muscle antibodies in evaluation of active thyroid-associated ophthalmopathy
- Published
- 2017
8. Darstellung einer Orbitametastase eines Dünndarmkarzinoids mittels Oktreotidszintigraphie Eine kritische Betrachtung der Methodik.
- Author
-
Guthoff, R., Lieb, W.E., Rendl, J., and Reiners, Chr.
- Abstract
Copyright of Der Ophthalmologe is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2000
- Full Text
- View/download PDF
9. European Association of Nuclear Medicine Practice Guideline/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma
- Author
-
Saeed Elojeimy, Henri J L M Timmers, Neeta Pandit-Taskar, Rodney J. Hicks, Anca M. Avram, Stefano Fanti, Aaron T. Scott, David Taïeb, Elif Hindié, Benjamin Guillet, Domenico Rubello, Karel Pacak, Pietro Ghedini, Irene Virgolini, Sona Balogova, Centre Européen de Recherche en Imagerie médicale (CERIMED), Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)-École Centrale de Marseille (ECM)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Centre National de la Recherche Scientifique (CNRS), Department of Cancer Imaging [Melbourne, Australie], Centre for Molecular Imaging [Melbourne, Australie], Peter MacCallum Cancer Centre [Melbourne, Australie]-Peter MacCallum Cancer Centre [Melbourne, Australie], Service de médecine nucléaire, CHU Bordeaux [Bordeaux], Centre recherche en CardioVasculaire et Nutrition = Center for CardioVascular and Nutrition research (C2VN), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), University of Michigan Medical School [Ann Arbor], University of Michigan [Ann Arbor], University of Michigan System-University of Michigan System, University hospital - Policlinico S.Orsola-Malpighi [Bologna, Italy], Radboud University Medical Center [Nijmegen], Johns Hopkins Hospital, Department of Nuclear Medicine, PET/CT Centre, The University of New Mexico [Albuquerque], Nuclear Medicine Unit [Bologna, Italy], Sant'Orsola-Malpighi Hospital [Bologna, Italy], Comenius University in Bratislava, Memorial Sloane Kettering Cancer Center [New York], Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), Intramural Research Program of NIH, NICHD, and Taïeb D, Hicks RJ, Hindié E, Guillet BA, Avram A, Ghedini P, Timmers HJ, Scott AT, Elojeimy S, Rubello D, Virgolini IJ, Fanti S, Balogova S, Pandit-Taskar N, Pacak K.
- Subjects
Positron emission tomography ,Radionuclide imaging ,[SDV]Life Sciences [q-bio] ,MESH: POSITRON-EMISSION-TOMOGRAPHY ,SOMATOSTATIN RECEPTOR SCINTIGRAPHY ,I-131/I-123-METAIODOBENZYLGUANIDINE MIBG SCINTIGRAPHY ,SDHX MUTATION CARRIERS ,F-18-DOPA PET-CT ,METASTATIC PHEOCHROMOCYTOMA ,F-18-FDG PET/CT ,IN-111-PENTETREOTIDE SCINTIGRAPHY ,I-123 METAIODOBENZYLGUANIDINE ,OCTREOTIDE SCINTIGRAPHY ,Adrenal Gland Neoplasms ,Pheochromocytoma ,Targeted radionuclide therapy ,Single-photon emission computed tomography ,Guideline ,Guidelines ,Somatostatin analogues ,Somatostatin analogue ,Article ,030218 nuclear medicine & medical imaging ,Iodine Radioisotopes ,Paraganglioma ,03 medical and health sciences ,0302 clinical medicine ,All institutes and research themes of the Radboud University Medical Center ,medicine ,media_common.cataloged_instance ,Humans ,Radiology, Nuclear Medicine and imaging ,European Union ,European union ,Societies, Medical ,media_common ,medicine.diagnostic_test ,business.industry ,Vascular damage Radboud Institute for Molecular Life Sciences [Radboudumc 16] ,General Medicine ,Phaeochromocytoma ,medicine.disease ,3. Good health ,030220 oncology & carcinogenesis ,Positron-Emission Tomography ,Radionuclide therapy ,Practice Guidelines as Topic ,Molecular imaging ,Nuclear Medicine ,Radiopharmaceuticals ,business ,Nuclear medicine ,Somatostatin ,Emission computed tomography - Abstract
Purpose: Diverse radionuclide imaging techniques are available for the diagnosis, staging, and follow-up of phaeochromocytoma and paraganglioma (PPGL). Beyond their ability to detect and localise the disease, these imaging approaches variably characterise these tumours at the cellular and molecular levels and can guide therapy. Here we present updated guidelines jointly approved by the EANM and SNMMI for assisting nuclear medicine practitioners in not only the selection and performance of currently available single-photon emission computed tomography and positron emission tomography procedures, but also the interpretation and reporting of the results. Methods: Guidelines from related fields and relevant literature have been considered in consultation with leading experts involved in the management of PPGL. The provided information should be applied according to local laws and regulations as well as the availability of various radiopharmaceuticals. Conclusion: Since the European Association of Nuclear Medicine 2012 guidelines, the excellent results obtained with gallium-68 (68Ga)-labelled somatostatin analogues (SSAs) in recent years have simplified the imaging approach for PPGL patients that can also be used for selecting patients for peptide receptor radionuclide therapy as a potential alternative or complement to the traditional theranostic approach with iodine-123 (123I)/iodine-131 (131I)-labelled meta-iodobenzylguanidine. Genomic characterisation of subgroups with differing risk of lesion development and subsequent metastatic spread is refining the use of molecular imaging in the personalised approach to hereditary PPGL patients for detection, staging, and follow-up surveillance.
- Published
- 2019
10. Distinct mechanisms of hypoglycaemia in patients with somatostatin‐secreting neuroendocrine tumours
- Author
-
Christoph Schmid, Aurel Perren, Michael Brändle, Peter Wiesli, Thomas Pfammatter, Vojtech Pavlicek, and University of Zurich
- Subjects
medicine.medical_specialty ,Pancreatic islet hyperplasia ,Endocrinology, Diabetes and Metabolism ,medicine.medical_treatment ,610 Medicine & health ,lcsh:Diseases of the endocrine glands. Clinical endocrinology ,Gastroenterology ,Internal medicine ,Diabetes mellitus ,Octreotide scintigraphy ,Biopsy ,neuroendocrine tumour ,medicine ,In patient ,somatostatinoma ,lcsh:RC648-665 ,medicine.diagnostic_test ,10042 Clinic for Diagnostic and Interventional Radiology ,business.industry ,Insulin ,nutritional and metabolic diseases ,Original Articles ,Somatostatinoma ,medicine.disease ,hyperinsulinaemia ,Somatostatin ,570 Life sciences ,biology ,Original Article ,business ,hormones, hormone substitutes, and hormone antagonists ,hypoglycaemia - Abstract
Introduction Somatostatin-secreting neuroendocrine tumours may present with diabetes, cholelithiasis and steatorrhoea. In addition, hypoglycaemia has been associated with somatostatinomas. However, the mechanism of hypoglycaemia in patients with somatostatinomas has not been well characterized. Methods We describe two patients with recurrent neuroglycopenic episodes caused by somatostatin-secreting neuroendocrine tumours in the liver, detected by abdominal CTs and whole-body octreotide scintigraphy scans and confirmed by biopsy. Results Pancreatic islet hyperplasia and co-secretion of insulin (in addition to somatostatin) from tumour cells, respectively, have been characterized as completely distinct mechanisms of hypoglycaemia at both the functional and morphological levels in these two patients. Conclusions Hypoglycaemia may be caused by different mechanisms in patients with somatostatinomas.
- Published
- 2019
11. Study of a Primary Gastrinoma in the Common Hepatic Duct – A Case Report.
- Author
-
Martignoni, M. E., Friess, H., Lübke, D., Uhl, W., Maurer, Ch., Müller, M., Richard, H.-P., Reubi, J.-C., and Büchler, M. W.
- Subjects
- *
CARCINOID , *NEUROENDOCRINE tumors , *ZOLLINGER-Ellison syndrome , *PEPTIC ulcer , *PANCREATIC tumors , *CHROMAFFIN cell tumors - Abstract
Primary endocrine neoplasms of the biliary tract are exceedingly rare. We report on a 60-year-old man with diarrhea, vomiting and gastroesophageal reflux disease, with a primary gastrinoma of the common hepatic duct. The tumor was positive for a variety of immunohistochemical markers. Postoperatively the patient’s symptoms disappeared and in the follow-up the patient was symptom free. To our knowledge, this is the first case in the literature of a primary gastrinoma in the common hepatic duct. The fact that the common hepatic duct is not located within the gastrinoma triangle made the diagnosis difficult and the distinct localization made the surgical treatment demanding. [ABSTRACT FROM AUTHOR]
- Published
- 1999
- Full Text
- View/download PDF
12. Somatostatin analogue scintigraphy in carcinoid tumours.
- Author
-
Kwekkeboom, Dik, Krenning, Eric, Bakker, Willem, Oei, H., Kooij, Peter, and Lamberts, Steven
- Abstract
Scintigraphy with iodine-123 or indium-111 labelled somatostatin analogue (octreotide) was performed in 52 patients diagnosed as, suspected of, or at risk of having carcinoid tumours. In 32 of 37 (86%) patients in whom histologically proven carcinoids were still present, known tumour sites were visualized. Using I-coupled octreotide, 24 of 40 (60%) known extrahepatic sites were visualized, whereas all of 12 (100%) extrahepatic lesions were visualized after injection of In-coupled octreotide. Known liver metastases were not distinctly visualized with octreotide scintigraphy in 12 of 24 patients. In all but two of these cases, an even distribution of radioactivity in the liver was observed. This is most probably due to the fact that these liver metastases accumulated about as much radioactivity as does normal liver tissue. Previously unsuspected localizations or sites not recognized with other imaging techniques were found in 20 of the 37 patients. In 3 of 11 patients who were thought to have been surgically cured, and in 4 of 4 patients who were suspected of having carcinoids, octreotide scintigraphy showed abnormal accumulation of radioactivity. Histological or radiological evidence that additional sites noticed on octreotide scintigrams indeed represented tumour tissue was obtained in ten patients. Visualization of the carcinoids did not depend on the site of the tumour or on the presence or absence of hormonal hypersecretion, as measured by urinary 5-hydroxyindoleacetic acid and serum α-subunit concentrations. Apart from its use for tumour localization, octreotide scintigraphy, in consequence of its ability to demonstrate somatostatin receptor positive tumours, could be used to select those patients with the carcinoid syndrome who are likely to respond favourably to octreotide treatment. [ABSTRACT FROM AUTHOR]
- Published
- 1993
- Full Text
- View/download PDF
13. Dural Arteriovenous Fistula Associated With a Vestibular Tumor: An Unusual Case and Review of the Literature
- Author
-
Bryan Pukenas, Omar Choudhri, Martin Oselkin, Douglas C. Bigelow, Robert W. Hurst, Sean M. Grady, Nikhil Sharma, David Kung, Michael E. Kritikos, and Pallavi P. Gopal
- Subjects
medicine.medical_specialty ,Hearing loss ,Neurosurgery ,Arteriovenous fistula ,Schwannoma ,Vestibular tumor ,angiogenesis ,03 medical and health sciences ,0302 clinical medicine ,vestibular schwannoma ,octreotide scintigraphy ,otorhinolaryngologic diseases ,medicine ,dural arteriovenous fistula ,medicine.diagnostic_test ,business.industry ,General Engineering ,intracranial tumor ,Magnetic resonance imaging ,medicine.disease ,Cerebellopontine angle ,Thrombosis ,somatostatin receptor ,030220 oncology & carcinogenesis ,Radiology ,medicine.symptom ,business ,030217 neurology & neurosurgery ,Cerebral angiography - Abstract
Intracranial dural arteriovenous fistulae (DAVF) are rare vascular malformations. They are generally considered to be acquired lesions, often attributed to dural sinus thrombosis and intracranial venous hypertension. The authors encountered a case of DAVF associated with an octreotide-positive vestibular schwannoma. A 46-year-old female had symptoms of right ear congestion accompanied by pulsatile tinnitus and mild hearing loss. Magnetic resonance imaging (MRI) identified a lobulated mass centered at the cerebellopontine angle. Preoperatively, on cerebral angiography, there was an incidental discovery of a DAVF in the right posterior fossa. The decision was made to proceed with resection of the tumor in a staged fashion. Her latest follow-up MRI showed no evidence of recurrent tumor. This is the second reported case of DAVF associated with an intracranial schwannoma. Findings are discussed along with a thorough review of the literature. This case, combined with the data from the literature review, led us to believe that tumor-related angiogenesis might contribute to DAVF formation.
- Published
- 2018
14. Metastatic Pancreatic Insulinoma with Gallium DOTATATE
- Author
-
Robert Matthews and Rajesh Gupta
- Subjects
Pancreatic Insulinoma ,business.industry ,Octreotide scintigraphy ,Recurrent disease ,medicine ,Neuroendocrine tumors ,Nuclear medicine ,business ,medicine.disease ,Mr imaging ,Insulinoma - Abstract
Ga-68 DOTATATE PET/MR imaging provides superior detection, localization, and characterization of pancreatic neuroendocrine tumors. It is excellent at detecting metastatic and recurrent disease and can detect therapy. Ga-68 DOTATATE has been shown to be superior to octreotide scintigraphy in the evaluation of these tumors.
- Published
- 2017
15. Thyrotropinoma with Graves’ disease detected by the fusion of indium-111 octreotide scintigraphy and pituitary magnetic resonance imaging
- Author
-
Erol Bolu, Abdullah Taslipinar, Kursat Okuyucu, Mehmet Salih Deveci, Nuri Arslan, and Engin Alagoz
- Subjects
Pituitary gland ,endocrine system ,endocrine system diseases ,Graves' disease ,030209 endocrinology & metabolism ,Thyrotropinoma ,Case Report ,03 medical and health sciences ,0302 clinical medicine ,Pituitary adenoma ,Female patient ,Octreotide scintigraphy ,thyroid-stimulating hormone-secreting pituitary adenoma ,medicine ,Radiology, Nuclear Medicine and imaging ,Pregnancy ,medicine.diagnostic_test ,business.industry ,Magnetic resonance imaging ,medicine.disease ,medicine.anatomical_structure ,indium-111 octreotide scintigraphy ,030220 oncology & carcinogenesis ,Nuclear medicine ,business ,Graves’ disease - Abstract
Thyroid-stimulating hormone-secreting pituitary adenoma (TSHoma) is a rare benign endocrinological tumor which produces TSH in the pituitary gland. Herein, we presented a female patient having TSHoma with Graves' disease during and just after pregnancy that we found by indium-111 octreotide scintigraphy while investigating the patient for hyperthyroidism symptoms.
- Published
- 2016
16. Malignant Insulinoma in Ectopic Pancreatic Tissue.
- Author
-
Hennings, Joakim, Garske, Ulrike, Botling, Johan, and Hellman, Per
- Subjects
- *
ISLANDS of Langerhans tumors , *PANCREAS , *CHROMAFFIN cell tumors , *DIGESTIVE organs , *ENDOCRINE glands - Abstract
Background: Both ectopic pancreatic tissue and malignant insulinoma are rare. We encountered the combination of these rare entities in a patient demonstrating hypoglycemic symptoms. Method: A patient with episodic hypoglycemia, non-suppressed serum insulin levels, positive fasting test and a positive localization on both ultrasound and somatostatin receptor scintigraphy by 111I-labelled octreotide, was operated and investigated. Results:111I-labelled octreotide-guided surgery was performed and a tumor adjacent to the ligament of Treitz was extirpated. Follow-up was uneventful. Histopathology revealed a malignant insulinoma. The patient is currently under close surveillance. Conclusion: The rare combination of an insulinoma in ectopic pancreatic tissue, where the usual diagnostic endoscopic ultrasound revealed an extrapancreatic mass, is described. This was followed by a positive somatostatin receptor scintigraphy, enabling both radio-guided surgery and future treatment of developing recurrent disease or metastases. Copyright © 2005 S. Karger AG, Basel [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
17. Visualization of Gallbladder with In-111 Octreotide Scan
- Author
-
Filiz Özülker, Tamer Özülker, M. Tarık Tatoğlu, and Aysun Küçüköz Uzun
- Subjects
lcsh:Medical physics. Medical radiology. Nuclear medicine ,Pathology ,medicine.medical_specialty ,lcsh:R895-920 ,lcsh:Medicine ,Case Report ,Spect imaging ,Octreotide scintigraphy ,Ingestion ,Medicine ,Fatty meal ,Radiology, Nuclear Medicine and imaging ,In-111-Octreotide ,gallbladder ,lcsh:R5-920 ,medicine.diagnostic_test ,business.industry ,Octreotide scan ,Gallbladder ,lcsh:R ,Tumor recurrence ,medicine.anatomical_structure ,neuroendocrine tumors ,business ,Nuclear medicine ,lcsh:Medicine (General) - Abstract
A 54-year-old woman underwent octreotide scintigraphy for evaluation of neuroendocrine tumor recurrence. The images demonstrated unusual uptake in gallbladder area in addition to physiologic uptake at other tissues. Whole-body planar and SPECT imaging were repeated after fatty meal ingestion at 28 hours in order to figure out whether this activity was physiologic or not. Since the unusual uptake in the gallbladder was still detected at these images, additional images were obtained 72 hours after radionuclide injection. The activity in the gallbladder disappeared at these images revealing the physiologic nature of this unusual accumulation.Elli dört yaşında bayan hastaya, nöroendokrin tümörün olası rekürrensinin saptanması amacıyla oktreotid sintigrafisi uygulandı. Görüntülerde, diğer dokulardaki fizyolojik tutulumlara ek olarak safra kesesi bölgesinde olağandışı tutulum gözlendi. Safra kesesindeki tutulumun fizyolojik olup olmadığının anlaşılabilmesi için 28. saatte yağlı yemek yenmesi sonrası tüm-vücut planar ve SPECT görüntüleri tekrarlandı. Safra kesesi bölgesindeki olağandışı aktivitenin bu görüntülerde de devam etmesi üzerine radyonüklidin enjeksiyonundan sonra 72. saatte görüntüler tekrarlandı. Bu görüntülerde safra kesesindeki aktivitenin kaybolması bu olağandışı tutulumun fizyolojik karakterde olduğunu gösterdi.
- Published
- 2015
18. 99mTc-HYNIC-TOC (99mTc-Hydrazinonicotinyl-Tyr3-Octreotide) Scintigraphy Identifying Two Separate Causative Tumors in a Patient With Tumor-Induced Osteomalacia (TIO)
- Author
-
Dingrong Zhong, Hongming Zhuang, Hongli Jing, and Fang Li
- Subjects
Male ,musculoskeletal diseases ,medicine.medical_specialty ,Bone Neoplasms ,Octreotide ,Culprit ,Lesion ,Unresected ,Octreotide scintigraphy ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Radionuclide Imaging ,Osteomalacia ,Foot ,business.industry ,Mesenchymal stem cell ,99mTc-HYNIC-TOC ,Organotechnetium Compounds ,General Medicine ,Humerus ,Middle Aged ,medicine.disease ,Phosphaturic mesenchymal tumor ,Radiology ,medicine.symptom ,business - Abstract
Tumors that cause osteomalacia are generally benign fibroblast growth factor-23 producing mesenchymal tumors which can be detected by octreoscan. A 45-year-old man underwent (99m)Tc-HYNIC-TOC scan to detect a possible culprit causing osteomalacia. The images showed abnormal activity in the left humerus and in the right foot. The lesion of the right foot was confirmed pathologically as phosphaturic mesenchymal tumor. After surgical removal of the tumor in the right foot, the patient's symptoms were promptly improved. However, the improvement was transient due to the unresected tumor in the left humerus.
- Published
- 2013
19. Small Bowel Neuroendocrine Tumors with Inguinal Metastases: A Diagnostic and Therapeutic Dilemma
- Author
-
Faisal Inayat, Farhad Askarian, Kevin P. Daly, and Muhammad Wasif Saif
- Subjects
Pathology ,medicine.medical_specialty ,business.industry ,Inguinal lymph nodes ,General Engineering ,Gastroenterology ,Neuroendocrine tumors ,medicine.disease ,03 medical and health sciences ,0302 clinical medicine ,medicine.anatomical_structure ,Peritoneum ,Oncology ,030220 oncology & carcinogenesis ,small bowel ,octreotide scintigraphy ,Octreotide scintigraphy ,medicine ,inguinal lymph node ,030212 general & internal medicine ,neuroendocrine tumors ,Mesentery ,business ,Radiology ,68ga-dotatate pet/ct - Abstract
Small bowel neuroendocrine tumors (NETs) are frequently characterized by a strong propensity to metastasize to the liver, mesentery, and peritoneum. However, only a few extra-abdominal metastatic sites have been reported in the published literature. The present paper implicates that primary small bowel NETs may unusually metastasize to the inguinal lymph nodes. Furthermore, we discuss the formidable diagnostic and therapeutic challenges associated with the metastatic NETs.
- Published
- 2016
20. Positron emission tomography/computed tomography imaging of adrenocorticotropic hormone-producing small-cell neuroendocrine carcinoma of the cervix
- Author
-
Ba D. Nguyen, Vien X. Nguyen, and Dora Lam-Himlin
- Subjects
0301 basic medicine ,medicine.medical_specialty ,Uterine Cervical Neoplasms ,Computed tomography ,Cervix Uteri ,Adrenocorticotropic hormone ,03 medical and health sciences ,0302 clinical medicine ,Adrenocorticotropic Hormone ,Positron Emission Tomography Computed Tomography ,Octreotide scintigraphy ,Humans ,Medicine ,Carcinoma, Small Cell ,Cervix ,Positron Emission Tomography-Computed Tomography ,medicine.diagnostic_test ,Neuroendocrine carcinoma of the cervix ,business.industry ,Obstetrics and Gynecology ,General Medicine ,Middle Aged ,medicine.disease ,Carcinoma, Neuroendocrine ,030104 developmental biology ,Small cell neuroendocrine carcinoma ,medicine.anatomical_structure ,Positron emission tomography ,030220 oncology & carcinogenesis ,Female ,Radiology ,business ,Nuclear medicine - Abstract
Ectopic ACTH-dependent Cushing syndrome-inducing small-cell neuroendocrine carcinoma of the cervix, undiagnosed by computed tomography and whole-body octreotide scintigraphy, was identified using F-18 FDG PET/CT imaging. This article is protected by copyright. All rights reserved.
- Published
- 2017
21. Cost comparison of 111In-DTPA-octreotide scintigraphy and 68Ga-DOTATOC PET/CT for staging enteropancreatic neuroendocrine tumours
- Author
-
Bernd Hamm, Munenobu Nogami, Ralph Buchert, Nils Schreiter, Ulrich-Frank Pape, Alexander Huppertz, Vikas Prasad, Martin H. Maurer, and Winfried Brenner
- Subjects
Adult ,Male ,medicine.medical_specialty ,Cost-Benefit Analysis ,Octreotide ,Multimodal Imaging ,68ga dotatoc ,Octreotide scintigraphy ,Organometallic Compounds ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Aged ,Neoplasm Staging ,PET-CT ,medicine.diagnostic_test ,Cost comparison ,business.industry ,Somatostatin receptor ,Diagnostic test ,Magnetic resonance imaging ,General Medicine ,Middle Aged ,Pentetic Acid ,Magnetic Resonance Imaging ,Pancreatic Neoplasms ,Neuroendocrine Tumors ,Positron emission tomography ,Positron-Emission Tomography ,Female ,Radiology ,Tomography, X-Ray Computed ,Nuclear medicine ,business - Abstract
Although somatostatin receptor positron emission tomography (PET)/CT is gaining increasing popularity and has shown its diagnostic superiority in several studies, (111)In-diethylenetriaminepentaacetic acid (DTPA)-octreotide is still the current standard for diagnosis of neuroendocrine tumours (NET). The aim of this study was to compare the costs for the two diagnostic tests and the respective consequential costs.From January 2009 to July 2009, 51 consecutive patients with enteropancreatic NET who underwent contrast-enhanced (68)Ga-DOTATOC PET/CT (n = 29) or (111)In-DTPA-octreotide (mean 3 whole-body scans plus 1.6 low-dose single photon emission computed tomography/CT; n = 22) were included. For cost analysis, direct costs (equipment) and variable costs (material, labour) per examination were calculated. Additionally required CT and/or MRI examinations within the staging process were assessed as consequential costs. An additional deterministic sensitivity analysis was performed.A (68)Ga-DOTATOC PET/CT examination yielded total costs (equipment, personnel and material costs) of 548 euro. On the other hand, an (111)In-DTPA-octreotide examination resulted in 827 euro total costs. Costs for equipment and material had a share of 460 euro/720 euro for (68)Ga-DOTATOC/(111)In-DTPA-octreotide and labour costs of 89 euro/106 euro. With (68)Ga-DOTATOC additional MRI had to be performed in 7% of the patients resulting in a mean of 20 euro for supplementary imaging per patient; 82% of patients with (111)In-DTPA-octreotide needed additional MRI and/or CT resulting in mean additional costs of 161 euro per patient.(68)Ga-DOTATOC PET/CT was considerably cheaper than (111)In-DTPA-octreotide with respect to both material and personnel costs. Furthermore, by using (68)Ga-DOTATOC PET/CT considerably fewer additional examinations were needed reducing the consequential costs significantly.
- Published
- 2011
22. New imaging approaches to phaeochromocytomas and paragangliomas
- Author
-
Bas Havekes, Kathryn S. King, Eleonora P M Corssmit, Johannes A. Romijn, Karel Pacak, Edwin W. Lai, Lifestyle Medicine (LM), Guided Treatment in Optimal Selected Cancer Patients (GUTS), Interne Geneeskunde, and RS: NUTRIM - R1 - Metabolic Syndrome
- Subjects
medicine.medical_specialty ,Pathology ,positron-emission-tomography metaiodobenzylguanidine mibg scintigraphy somatostatin receptor subtype-2 subunit-b gene metastatic pheochromocytoma neuroendocrine tumors i-123 metaiodobenzylguanidine extraadrenal pheochromocytoma malignant paragangliomas diagnostic localization ,SDHB ,Endocrinology, Diabetes and Metabolism ,Adrenal Gland Neoplasms ,Context (language use) ,Pheochromocytoma ,Gene mutation ,Article ,Paraganglioma ,Endocrinology ,Internal medicine ,Medicine ,Humans ,OCTREOTIDE SCINTIGRAPHY ,HEAD ,Radionuclide Imaging ,SUPERIOR ,medicine.diagnostic_test ,business.industry ,Magnetic resonance imaging ,medicine.disease ,NECK PARAGANGLIOMAS ,Magnetic Resonance Imaging ,Functional imaging ,Radiography ,Positron emission tomography ,Positron-Emission Tomography ,business ,Somatostatin - Abstract
Formerly used concepts for phaeochromocytomas and paragangliomas have been challenged by recent discoveries that at least 24% of tumours are familial and thereby often multiple in various locations throughout the body. Furthermore, tumours are often malignant and perhaps more aggressive if associated with SDHB gene mutations. Some paragangliomas are clinically silent and may present only with dopamine hypersecretion. In the current era where CT and MRI are more commonly used, tumours are more often found as incidentalomas and MRI may be less specific for phaeochromocytoma and paraganglioma than previously thought. Because of unique tumour characteristics (e.g. the presence of cell membrane and intracellular vesicular norepinephrine transporters) these tumours were 'born' to be imaged by means of specific functional imaging approaches. Moreover, additional recent discoveries related to apoptosis, hypoxia, acidosis, anaerobic glycolysis and angiogenesis, often disturbed in tumour cells, open new options and challenges to specifically image phaeochromocytomas and paragangliomas and possibly link those results to their pathophysiology, genotypic alterations and metastatic potential. Functional imaging, especially represented by positron emission tomography (PET), offers an excellent approach by which tumour-specific processes can be detected, evaluated and seen in the context of tumour-specific behaviour and its genetic signature. In this review, we address the recent developments in new functional imaging modalities for phaeochromocytoma and paraganglioma and provide the reader with suggested imaging approaches in various phaeochromocytomas and paragangliomas of sympathetic origin. Current imaging algorithms of head and neck parasympathetic paragangliomas are not discussed. Finally, this review outlines some future perspectives of functional imaging of these tumours.
- Published
- 2010
23. Detection of the primary tumor site in tumor-induced osteomalacia by indium-111 octreotide scintigraphy: A case report
- Author
-
Syuta Toru, Kiyohumi Ota, Hajime Izumiyama, Makoto Takahashi, Hidehiro Mizusawa, and Takanori Yokota
- Subjects
Adult ,medicine.medical_specialty ,Hypophosphatemia ,Paraneoplastic Syndromes ,Octreotide ,Soft Tissue Neoplasms ,Octreotide scintigraphy ,medicine ,Humans ,Mesenchymoma ,Family history ,Radionuclide Imaging ,Osteomalacia ,Foot ,business.industry ,Indium Radioisotopes ,Muscle weakness ,medicine.disease ,Primary tumor ,Fibroblast Growth Factors ,Fibroblast Growth Factor-23 ,Renal physiology ,Female ,Neurology (clinical) ,Radiology ,Radiopharmaceuticals ,medicine.symptom ,business ,medicine.drug - Abstract
We report a 31-year-old woman with tumor-induced osteomalacia suffering from slowly progressive bilateral muscle weakness predominantly in the proximal muscles and multiple bone pains for the past 2 years. She was unable to walk or raise her arms above the shoulder. We suspected tumor-induced osteomalacia due to decreased serum phosphate and 1alpha, 25 (OH),-vitamin D3 levels, low percentage of tubular reabsorption of phosphate (%TRP), adult onset, and no family history of osteomalacia. Regular imaging examinations could not detect the location of the primary tumor: however, indium-111 octreotide scintigraphy detected the causative primary mesenchymal tumor in the right sole. Pain and muscle weakness improved promptly after tumor resection, and she was able to walk 6 d postoperatively. This is the first case report in Japan describing the detection of the primary tumor site by indium-111 octreotide scintigraphy.
- Published
- 2008
24. The Role of Octreotide Scintigraphy in Clinical Diagnosis and Therapy
- Author
-
E. P. Krenning, S. W. J. Lamberts, and D. J. Kwekkeboom
- Subjects
medicine.medical_specialty ,Endocrinology ,business.industry ,Internal medicine ,Clinical diagnosis ,Octreotide scintigraphy ,medicine ,Radiology ,business - Published
- 2015
25. Usefulness of[111In-DTPA0] octreotide scintigraphy in a family with von Hippel-Lindau disease
- Author
-
Pulcrano, M., Camera, L., Pagano, L., Del Vecchio, S., Ferone, D., Bodei, L., Murgia, A., Pace, L., Storto, G., Paganelli, G., Colao, A., Salvatore, M., Lombardi, G., and Biondi, B.
- Published
- 2008
- Full Text
- View/download PDF
26. ACTH-produzierendes Paragangliom der Nasennebenh�hlen
- Author
-
R. Münzenmaier, B. Lieberum, and C. Jaspers
- Subjects
Otorhinolaryngology ,business.industry ,Ectopic ACTH syndrome ,Octreotide scintigraphy ,Head and neck surgery ,Medicine ,business ,Neuroendocrine tumour - Abstract
Paragangliome werden den neuroendokrinen Tumoren zugeordnet und produzieren als solche gelegentlich Peptidhormone.Sehr selten kommen sie auch in der Nase und/oder den Nasennebenhohlen vor. Beschrieben wird der nach unserer Erkenntnis erste Fall eines rezidivierenden nasalen Paraganglioms, das nach zehnjahrigem endokrinologisch unauffalligem Krankheitsverlauf zu einem Cushing-Syndrom durch ektope ACTH-Produktion fuhrte. Nach chirurgischer Therapie kam es zu einer Normalisierung der ACTH- und Kortisolwerte.
- Published
- 2003
27. Is 68Ga-DOTATATE the answer in lung carcinoid? : Case report and review of literature
- Author
-
Amit Bhoil, Raghava Kashyap, Shankaramurthy Gayana, Anish Bhattacharya, Navneet Singh, and Bhagwant Rai Mittal
- Subjects
lcsh:RC705-779 ,Pulmonary and Respiratory Medicine ,PET-CT ,medicine.medical_specialty ,Lung ,business.industry ,Somatostatin receptor ,FDG ,PET/CT ,Carcinoid tumors ,Case Report ,lcsh:Diseases of the respiratory system ,68Ga-DOTATATE ,medicine.disease ,Lung carcinoid ,High uptake ,medicine.anatomical_structure ,Octreotide scintigraphy ,Medicine ,Radiology ,business ,Nuclear medicine - Abstract
Carcinoid tumors are rich in somatostatin receptors and show high uptake of radiotracer on octreotide scintigraphy. 68Ga-DOTATATE could be of great help at initial staging and during follow-up of these patients. We describe a patient with avid 68Ga-DOTATATE and poor F18-FDG uptake.
- Published
- 2012
28. ACTH-produzierendes Paragangliom der Nasennebenhöhlen
- Author
-
Lieberum, B., Jaspers, C., and Münzenmaier, R.
- Published
- 2003
- Full Text
- View/download PDF
29. Octreotide scintigraphy for the detection of paragangliomas
- Author
-
Michelle L. Hansman Whiteman, Thomas J. Balkany, Fred F. Telischi, Orlando Gomez-Marin, Andres Bustillo, Michael J. Reisberg, Francisco J. Civantos, and Aldo N. Serafini
- Subjects
Male ,medicine.medical_specialty ,Octreotide ,Neuroendocrine tumors ,Neoplasms, Multiple Primary ,Paraganglioma ,03 medical and health sciences ,0302 clinical medicine ,Predictive Value of Tests ,Octreotide scintigraphy ,Medicine ,Humans ,Receptors, Somatostatin ,030223 otorhinolaryngology ,Tomography, Emission-Computed, Single-Photon ,Preoperative planning ,medicine.diagnostic_test ,business.industry ,Octreotide scan ,medicine.disease ,Otorhinolaryngologic Neoplasms ,Somatostatin ,Otorhinolaryngology ,Predictive value of tests ,030220 oncology & carcinogenesis ,Histopathology ,Female ,Surgery ,Radiology ,business ,medicine.drug - Abstract
Paragangliomas are neuroendocrine tumors located primarily in the head and neck region, but they can also occur at other sites. Confirming the preoperative diagnosis and detecting synchronous tumors may be difficult in some patients. Octreotide is a somatostatin analog that, when coupled to a radioisotope, produces a scintigraphic image of tumors expressing somatostatin type 2 receptors. Paragangliomas, like many neuroendocrine tumors, have been found to have a high density of somatostatin type 2 receptors on the cell surface. This study compared the results of preoperative octreotide scintigraphy with the histopathology in 21 patients who underwent surgery for presumed head and neck paragangliomas. Octreotide scan findings were positive in 16 patients with paragangliomas and negative in 3 patients with other pathology. One false-positive and 1 false-negative result were obtained. Thus, this test had an accuracy of 90%, a sensitivity of 94%, and a specificity of 75%. Previously unidentified synchronous tumors were identified in 5 patients. On the basis of this series of patients, octreotide scintigraphy appears to be a reliable test to detect paragangliomas and may be quite helpful in preoperative planning.
- Published
- 2000
30. A case of facial nerve schwannoma with positive octreotide scintigraphy
- Author
-
R. Pastourel, T. Mom, Laurent Gilain, and V. Dupuch
- Subjects
medicine.medical_specialty ,Otorhinolaryngology ,business.industry ,Octreotide scintigraphy ,Medicine ,Surgery ,Radiology ,Schwannoma ,business ,Head and neck ,medicine.disease ,Facial nerve - Abstract
European Annals of Otorhinolaryngology, Head and Neck Diseases - Vol. 132 - N° 2 - p. 113-114
- Published
- 2015
31. Tumor-Induced Osteomalacia and the Importance of Plasma Fibroblast Growth Factor 23 as an Indicator: Diagnostic Delay Leads to a Suicide Attempt.
- Author
-
Seemann L, Padala SA, Mohammed A, and Belayneh N
- Subjects
- Delayed Diagnosis psychology, Female, Fibroblast Growth Factor-23, Fibromyalgia etiology, Humans, Hypophosphatemia etiology, Magnetic Resonance Imaging, Middle Aged, Neoplasms, Connective Tissue blood, Neoplasms, Connective Tissue complications, Osteomalacia, Pain etiology, Paraneoplastic Syndromes blood, Paraneoplastic Syndromes complications, Phosphates blood, Radionuclide Imaging, Rickets, Hypophosphatemic etiology, Fibroblast Growth Factors blood, Neoplasms, Connective Tissue diagnosis, Paraneoplastic Syndromes diagnosis, Suicide, Attempted psychology
- Abstract
Tumor-induced osteomalacia is a rare hypophosphatemic disease caused by unregulated production of fibroblast growth factor 23 by a tumor, thereby inducing renal phosphate wasting and inhibiting appropriate increase of calcitriol production. Symptoms of tumor-induced osteomalacia, including muscle weakness, bone pain, and pathologic fractures, are nonspecific and warrant further workup. We report the case of a 50-year-old African American female with no known psychiatric illness who was admitted after a failed suicide attempt provoked by severe bone pain. She had been treated for fibromyalgia and hypophosphatemic rickets at other facilities with no improvement. The findings of profound renal phosphate wasting initiated further evaluation, which revealed an elevated fibroblast growth factor 23 level and a right proximal fibular mesenchymal tumor on octreotide scintigraphy. Magnetic resonance imaging confirmed the findings of a solid intramuscular tumor corresponding to the octreotide avid lesion. After wide excision of the tumor, serum phosphate and parathyroid hormone levels began to normalize. This case highlights the importance of extensively investigating the cause of bone pain, weakness, and fatigue in patients without a family history of hypophosphatemia or bone disorders. The aforementioned symptoms may precede recurrent pathological fractures, and a thorough workup ensures that a diagnosis of tumor is not delayed or overlooked, as tumor resection confers a favorable prognosis and dramatic increase in the quality of life for patients.
- Published
- 2019
- Full Text
- View/download PDF
32. Primary ovarian carcinoid: value of octreotide scintigraphy for diagnosis and correlation with other cross-sectional imaging modalities and pathology
- Author
-
V Trapanotto, A Gordon, U M Hamper, A S Krasner, and Ali Cahid Civelek
- Subjects
Adult ,Diagnostic Imaging ,Pathology ,medicine.medical_specialty ,Octreotide ,Ovary ,Carcinoid Tumor ,Octreotida ,Scintigraphy ,Cross-sectional imaging ,Octreotide scintigraphy ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Radionuclide Imaging ,Ovarian Neoplasms ,Modalities ,Radiological and Ultrasound Technology ,medicine.diagnostic_test ,business.industry ,Indium Radioisotopes ,Hydroxyindoleacetic Acid ,Magnetic Resonance Imaging ,medicine.anatomical_structure ,Female ,Histopathology ,Tomography, X-Ray Computed ,business ,medicine.drug - Published
- 1997
33. Localization and postoperative follow-up of a bronchial carcinoid tumor causing Cushing’s syndrome by 111In-DTPA labelled octreotide scintigraphy
- Author
-
L. Flores, F. Fernandez-Fernandez, Irene Halperin, J. M. Manzanares, F. Lomeña, and Vilardell E
- Subjects
Adult ,Male ,endocrine system ,medicine.medical_specialty ,Pathology ,Endocrinology, Diabetes and Metabolism ,Carcinoid Tumor ,Octreotide ,Scintigraphy ,Dexamethasone ,Cushing syndrome ,Endocrinology ,Adrenocorticotropic Hormone ,Octreotide scintigraphy ,medicine ,Humans ,Radionuclide Imaging ,Cushing Syndrome ,Glucocorticoids ,Bronchus ,S syndrome ,medicine.diagnostic_test ,business.industry ,Bronchial Neoplasms ,Indium Radioisotopes ,Respiratory disease ,BRONCHIAL CARCINOID TUMOR ,Pentetic Acid ,medicine.disease ,Occult ,Kinetics ,medicine.anatomical_structure ,Radiology ,business - Abstract
Bronchial carcinoid tumor is the most frequent occult source of ectopic ACTH-dependent Cushing’s syndrome, but its initial localization may be very difficult, as well as its postoperative follow-up. We here present the case of a 21 -year-old man with Cushing’s syndrome and biochemical findings suggesting an ectopic source of ACTH (lack of inhibition of Cortisol after overnight 8-mg dexametha-sone supression test, and lack of response to h-CRH challenge). Chest CT-scan showed a node adjacent to the left lung hilium whose nature was confirmed by uptake of 111Indium-DTPA labelled octreotide scintigraphy. Surgical resection of the tumor consisted in an upper lobectomy of the left lung. Microscopic examination identified a typical carcinoid tumor. After surgery pituitary-adrenal function normalized and a second scintigraphy offered additional data on the absence of tumor remnants.
- Published
- 1997
34. Malignant Insulinoma in Ectopic Pancreatic Tissue
- Author
-
Per Hellman, Johan Botling, Ultike Garske, and Joakim Hennings
- Subjects
endocrine system ,medicine.medical_specialty ,Pathology ,endocrine system diseases ,Ectopic pancreatic tissue ,Choristoma ,Octreotide ,Internal medicine ,Octreotide scintigraphy ,Humans ,Medicine ,Radionuclide Imaging ,Pancreas ,Aged ,business.industry ,Gastroenterology ,Malignant insulinoma ,Hypoglycemia ,Pancreatic Neoplasms ,Endocrinology ,Ectopic pancreas ,Female ,Insulinoma ,Surgery ,Radiopharmaceuticals ,business - Abstract
Both ectopic pancreatic tissue and malignant insulinoma are rare. We encountered the combination of these rare entities in a patient demonstrating hypoglycemic symptoms.A patient with episodic hypoglycemia, non-suppressed serum insulin levels, positive fasting test and a positive localization on both ultrasound and somatostatin receptor scintigraphy by (111)I-labelled octreotide, was operated and investigated.(111)I-labelled octreotide-guided surgery was performed and a tumor adjacent to the ligament of Treitz was extirpated. Follow-up was uneventful. Histopathology revealed a malignant insulinoma. The patient is currently under close surveillance.The rare combination of an insulinoma in ectopic pancreatic tissue, where the usual diagnostic endoscopic ultrasound revealed an extrapancreatic mass, is described. This was followed by a positive somatostatin receptor scintigraphy, enabling both radio-guided surgery and future treatment of developing recurrent disease or metastases.
- Published
- 2005
35. Clinical value of technetium-99m-labeled octreotide scintigraphy in local recurrent or metastatic medullary thyroid cancers: a comparison of lesions with 18F-FDG-PET and MIBI images
- Author
-
Metin Halac, Meltem Ocak, Sait Sager, Gunes Sager, Levent Kabasakal, Bedii Kanmaz, Çetin Önsel, Sertac Asa, Lebriz Uslu, and Helmut Maecke
- Subjects
Adult ,Male ,Technetium Tc 99m Sestamibi ,medicine.medical_specialty ,Medullary cavity ,Adolescent ,Octreotide ,18f fdg pet ,HYNIC-tyrosine octreotide ,Young Adult ,Fluorodeoxyglucose F18 ,octreotide scintigraphy ,medicine ,Tc-99m MIBI ,Humans ,Radiology, Nuclear Medicine and imaging ,Thyroid Neoplasms ,Neoplasm Metastasis ,HYNIC-TATE ,Aged ,medicine.diagnostic_test ,business.industry ,18F-fluorodeoxyglucose-PET ,Thyroid ,Medullary thyroid cancer ,General Medicine ,Original Articles ,Middle Aged ,medicine.disease ,Carcinoma, Neuroendocrine ,medicine.anatomical_structure ,Positron emission tomography ,Positron-Emission Tomography ,Female ,Radiology ,Neoplasm Recurrence, Local ,business ,Technetium-99m ,medicine.drug - Abstract
Aim Various studies have been conducted for determining the most optimal method for the early diagnosis of local recurrent or distant metastatic thyroid cancers. The aim of this study was to evaluate the clinical utility of technetium-99m (Tc-99m)-labeled octreotide derivatives in the detection of recurrence or distant metastases in medullary thyroid cancer patients and to compare the lesions with those detected using 18F-fluorodeoxyglucose (18F-FDG)-PET and Tc-99m MIBI studies in the same patient group. Patients and methods Sixteen medullary thyroid cancer patients [two male and 14 female; mean age 52.0±14.1 years (range 13–72 years)] were included in this study. All patients underwent a whole-body scan 1 and 4 h after injection with octreotide derivatives and single photon emission computed tomography images were taken of the sites suspicious for metastasis. The lesions seen in Tc-99m HYNIC octreotide studies were compared with those seen in 18F-FDG-PET and Tc-99m MIBI studies. Results Among the Tc-99m-labeled octreotide scintigraphy studies, nine were evaluated as true positive (56.2%) and one was evaluated as false positive (6.2%); six were false negative (37.5%). In 16 patients, the total number of lesions seen on octreotide scintigraphy was 21. Thirteen of the 16 patients underwent 18F-FDG-PET imaging. Of the 13 patients studied, 10 showed true-positive (76.9%) and three showed false-negative (23.1%) results. The total number of lesions seen on 18F-FDG-PET was 23. The Tc-99m MIBI study yielded positive results in seven of 16 patients (43.7%) and negative results in nine patients (56.3%). The total number of lesions on Tc-99m MIBI was 12. Conclusion The Tc-99m-labeled somatostatin receptor scintigraphy analogs HYNIC-tyrosine octreotide and HYNIC-TATE are useful imaging alternatives in somatostatin receptor-expressing thyroid cancers. Radiolabeling using these analogs is easy and they are readily available for routine use.
- Published
- 2013
36. In-111 Octreotide Scintigraphy in the Diagnostic Evaluation of En Plaque Meningioma
- Author
-
Anna Tofani, Raffaele P. Cioffi, Rosa Sciuto, Enzo Morace, Carlo Ludovico Maini, Marcello Crecco, and Marcella Mottolese
- Subjects
Adult ,Hyperostosis ,Diagnostic evaluation ,Octreotide ,Scintigraphy ,Meningioma ,Octreotide scintigraphy ,Meningeal Neoplasms ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Frontal region ,Radionuclide Imaging ,medicine.diagnostic_test ,business.industry ,Indium Radioisotopes ,Magnetic resonance imaging ,General Medicine ,medicine.disease ,Magnetic Resonance Imaging ,Skull deformity ,Female ,Tomography, X-Ray Computed ,Nuclear medicine ,business - Abstract
A 44-year-old woman had a 13-year history of a small bulge of the left frontal region which had increased in size during the last year. At admission, an orange-sized, hard, fixed left frontal mass was found. Magnetic resonance imaging showed hyperostosis in the left frontal region which was causing a skull deformity and marked focal meningeal enhancement. A hyperostotic plaque meningioma was hypothesized. In-111 octreotide scintigraphy confirmed the diagnosis before surgery. In-111 octreotide scintigraphy allows biologic characterization of neoplasms in vivo.
- Published
- 1995
37. Diagnosis and treatment of lymph node metastases of a rectal carcinoid tumor using In111-octreotide-scintigraphy and intraoperative gamma probe detection
- Author
-
T Travaglia, P Rossini, M Odeh, A Rossetti, L Arru, and F Ragni
- Subjects
Gamma-probe ,medicine.medical_specialty ,Rectal Carcinoid ,Node metastasis ,business.industry ,Colorectal cancer ,Carcinoids ,Less invasive ,Case Report ,medicine.disease ,digestive system diseases ,Surgery ,medicine.anatomical_structure ,Octreoscan ,Octreotide scintigraphy ,medicine ,Rectal ,Radiology ,Node metastases ,business ,Lymph node ,neoplasms ,Rectal Carcinoid Tumor ,Gamma probe - Abstract
Carcinoids represent 1–2% of the rectal cancer. We report the case of a woman with a rectal carcinoid and a hypogastric node metastasis. We propose a less invasive treatment of the metastase using In11-octreotide-scintigraphy and intraoperative gamma-probe detector.
- Published
- 2011
38. Demonstration of Non–Small-Cell Lung Carcinoma by Indium-111 Octreotide Scintigraphy
- Author
-
Ba D. Nguyen and Michael C. Roarke
- Subjects
Lung Neoplasms ,Antineoplastic Agents, Hormonal ,chemistry.chemical_element ,Octreotide ,Carcinoma, Non-Small-Cell Lung ,Octreotide scintigraphy ,Carcinoma ,Humans ,Medicine ,Radiology, Nuclear Medicine and imaging ,Tomography, Emission-Computed, Single-Photon ,Lung ,business.industry ,Indium Radioisotopes ,General Medicine ,Middle Aged ,medicine.disease ,medicine.anatomical_structure ,chemistry ,Non small cell ,Nuclear medicine ,business ,Indium ,medicine.drug - Published
- 2000
39. Increased activity on In-111 octreotide imaging due to radiation fibrosis
- Author
-
Chuong Bui, Robert Mansberg, Leo Ha, and Diep N. Nguyen
- Subjects
endocrine system ,Pathology ,medicine.medical_specialty ,Medullary cavity ,Octreotide ,Breast Neoplasms ,Thyroid carcinoma ,Diagnosis, Differential ,Octreotide scintigraphy ,Pulmonary fibrosis ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,False Positive Reactions ,Radiation fibrosis ,business.industry ,Somatostatin receptor ,General Medicine ,Middle Aged ,medicine.disease ,Radiation Pneumonitis ,Female ,Non small cell ,Radiopharmaceuticals ,business ,medicine.drug ,Tomography, Emission-Computed - Abstract
Indium-111 octreotide scintigraphy is a useful investigation in the diagnosis and staging neuroendocrine or nonendocrine malignancies such as carcinoid, granulomas, small cell lung cancer, medullary thyroid carcinoma, and others. Tumors with large numbers of somatostatin receptors can be accurately imaged and this can be useful in guiding treatment. Although uncommon, false-positives studies have been reported and often the cause is unexplained but assumed to be a high number of somatostatin receptors in other pathology. We present a case with increased uptake resulting in a scan due to pulmonary fibrosis.
- Published
- 2007
40. Cardiac pheochromocytomas detected by Tc-99m-hydrazinonicotinyl-Tyr3-octreotide (HYNIC-TOC) scintigraphy
- Author
-
Hongming Zhuang, Fang Li, Zhengpei Zeng, Libo Chen, Hongli Jing, and Yanrong Du
- Subjects
Adult ,Male ,endocrine system ,endocrine system diseases ,Adolescent ,Pheochromocytoma ,Scintigraphy ,Octreotide ,Diagnosis, Differential ,Heart Neoplasms ,Tc-99m hydrazinonicotinyl-Tyr3-octreotide ,Adrenal Pheochromocytoma ,Preliminary report ,Octreotide scintigraphy ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Radionuclide Imaging ,neoplasms ,Retrospective Studies ,medicine.diagnostic_test ,business.industry ,General Medicine ,Organotechnetium Compounds ,medicine.disease ,nervous system ,Female ,Radiopharmaceuticals ,Nuclear medicine ,business ,hormones, hormone substitutes, and hormone antagonists ,Extraadrenal Pheochromocytoma - Abstract
Primary pheochromocytomas of the heart are extremely rare tumors and difficult to diagnose. Iodine labeled metaiodobenzylguanidine (MIBG) is the first choice of the nuclear medicine modality in the evaluation of adrenal pheochromocytoma. However, the sensitivity of MIBG in the diagnosis of extraadrenal pheochromocytoma is less optimal. In this preliminary report, the efficacy of octreotide scintigraphy using Tc-99m labeled hydrazinonicotinyl-Tyr3-octreotide (HYNIC-TOC) in the evaluation of primary cardiac pheochromocytoma was assessed.
- Published
- 2007
41. 875 Cellular Proliferation Does Not Correlate With Octreotide Scintigraphy Findings in GI Neuroendocrine Tumors
- Author
-
Samuel J. Wahl, Hetal N. Trivedi, Matthew E. Maeder, Joanne Weiskopf, Samantha L. Savitch, Paresh C. Shah, Solaiman Futuri, Stephen C. Scharf, and Stephen Machnicki
- Subjects
Pathology ,medicine.medical_specialty ,Hepatology ,business.industry ,Octreotide scintigraphy ,Gastroenterology ,Medicine ,Neuroendocrine tumors ,business ,medicine.disease - Published
- 2015
42. Indium 111 Octreotide Scintigraphy in Angiofibroma
- Author
-
Hatice Durak, Enis Alpin Güneri, Semih Sütay, Berna Degirmenci, Ahmet Omer Ikiz, and Erkan Derebek
- Subjects
Adult ,Male ,Nose Neoplasms ,chemistry.chemical_element ,Angiofibroma ,Octreotide ,03 medical and health sciences ,0302 clinical medicine ,Octreotide scintigraphy ,medicine ,Humans ,Receptors, Somatostatin ,030223 otorhinolaryngology ,Tomography, Emission-Computed, Single-Photon ,business.industry ,Indium Radioisotopes ,Pentetic Acid ,medicine.disease ,Otorhinolaryngology ,chemistry ,030220 oncology & carcinogenesis ,Surgery ,Radiopharmaceuticals ,Nuclear medicine ,business ,Indium - Published
- 1998
43. Nuclear radiation dose to the surroundings from patients who are undergoing nuclear medicine examinations
- Author
-
Geir Andre Pedersen, Liv-Inger Stenstad, Berit Brattheim, and Andreas D. Landmark
- Subjects
lcsh:Medical physics. Medical radiology. Nuclear medicine ,medicine.diagnostic_test ,business.industry ,lcsh:R895-920 ,Radiation dose ,Building and Construction ,Staff education ,radiopharmaceutical ,Nuclear radiation ,surroundings ,Bone scintigraphy ,Nuclear medicine ,Octreotide scintigraphy ,medicine ,Anxiety ,quantitative research methodology ,medicine.symptom ,Radiation protection ,radiation dose ,nuclear medicine technologists ,business ,radiation protection - Abstract
The worldwide 2009 estimates for the average annual per-capita effective radiation dose from medicine have doubled during the past 15 years. This has increased the concern for patients as radiation sources. The existing evidence indicates that the amount of radiation is small; but there are few empirical studies with results documenting the actual extent. In this study, we examined the radiation from 48 patients undergoing nuclear medical examination. 20 patients were examined with bone scintigraphy, 20 underwent MUGA, while the remaining 8 went through octreotide scintigraphy procedure. At 0.25 meters from the patient, the radiation ranged from 31±9 µSvh-1 for octreotide scintigraphy patients (111-In as agent), 69±13 µSvh-1 for bone scintigraphy (99mTc), to 92±26 µSvh-1 for the MUGA patients (99mTc). On the basis of these findings and others, one may consider current practices regarding waiting and using led shielding in areas where appropriate. Perhaps, and more important, these results could be used to improve patient and staff education. Better information material with more evidence will reduce undue anxiety.
- Published
- 2014
44. Dural Arteriovenous Fistula Associated With a Vestibular Tumor: An Unusual Case and Review of the Literature.
- Author
-
Kritikos ME, Oselkin M, Sharma N, Gopal PP, Bigelow DC, Grady S, Hurst RW, Pukenas BA, Choudhri O, and Kung D
- Abstract
Intracranial dural arteriovenous fistulae (DAVF) are rare vascular malformations. They are generally considered to be acquired lesions, often attributed to dural sinus thrombosis and intracranial venous hypertension. The authors encountered a case of DAVF associated with an octreotide-positive vestibular schwannoma. A 46-year-old female had symptoms of right ear congestion accompanied by pulsatile tinnitus and mild hearing loss. Magnetic resonance imaging (MRI) identified a lobulated mass centered at the cerebellopontine angle. Preoperatively, on cerebral angiography, there was an incidental discovery of a DAVF in the right posterior fossa. The decision was made to proceed with resection of the tumor in a staged fashion. Her latest follow-up MRI showed no evidence of recurrent tumor. This is the second reported case of DAVF associated with an intracranial schwannoma. Findings are discussed along with a thorough review of the literature. This case, combined with the data from the literature review, led us to believe that tumor-related angiogenesis might contribute to DAVF formation., Competing Interests: The authors have declared that no competing interests exist.
- Published
- 2018
- Full Text
- View/download PDF
45. Positive octreotide scintigraphy and determination of lanreotide activity in Paget's disease of bone associated with phosphate diabetes: a case report
- Author
-
Didier Blocklet, Xavier Vandemergel, and Guy Decaux
- Subjects
medicine.medical_specialty ,Phosphate diabetes ,Endocrinology, Diabetes and Metabolism ,Pain ,Scintigraphy ,Lanreotide ,Peptides, Cyclic ,chemistry.chemical_compound ,Endocrinology ,Internal medicine ,Octreotide scintigraphy ,medicine ,Humans ,Femur ,Radionuclide Imaging ,Hypophosphatemia, Familial ,Aged ,Gynecology ,Aged, 80 and over ,medicine.diagnostic_test ,business.industry ,Phosphorus ,General Medicine ,medicine.disease ,Phosphate ,Alkaline Phosphatase ,Osteitis Deformans ,Paget s disease ,Paget's disease of bone ,chemistry ,Parathyroid Hormone ,Calcium ,business ,Somatostatin - Abstract
Nous rapportons le cas d’un patient presentant une maladie de Paget osseuse associee a un diabete phosphate (phosphate :1,6 mg/dl (2.5-4.4 mg/dl), la clearance du phosphate est de 29 ml/’ (nl 85 %). Nous avons teste l’hypothese (comme recemment demontree lors de diabete phosphate associe aux tumeurs) d’une amelioration du diabete phosphate lors de l’administration d’analogue de la somatostatine. Le patient a beneficie d’une scintigraphie a l’octreotide marque a l’Indium-111 demontrant une captation dans l’os pagetique. Sous Lanreotide (40 mg IM), le patient a presente une amelioration des douleurs osseuses avec diminutions du taux de phosphatase alcaline. La clearance de phosphate et le taux de reabsorption tubulaire de phosphate ne sont pas modifies. Nous rapportons egalement les autres cas associant une maladie de Paget et un diabete phosphate.
- Published
- 2004
46. Eventration as a cause of thoracic uptake on In-111 octreotide scintigraphy
- Author
-
Paul Roach, Tamara Nowland, and Allison Malcolm
- Subjects
medicine.medical_specialty ,Octreotide ,Octreotide scintigraphy ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,False Positive Reactions ,Gastrin ,Aged ,Aged, 80 and over ,Tomography, Emission-Computed, Single-Photon ,Gastrinoma ,medicine.diagnostic_test ,business.industry ,Octreotide scan ,Stomach ,Indium Radioisotopes ,Left hemidiaphragm ,General Medicine ,Diaphragmatic Eventration ,medicine.disease ,medicine.anatomical_structure ,Female ,Radiology ,Chest radiograph ,business ,Nuclear medicine ,Tomography, X-Ray Computed ,medicine.drug - Abstract
An 81-year-old woman with an elevated serum gastrin level underwent an In-111 octreotide scan for evaluation of a possible gastrinoma. Planar and SPECT images acquired 24 and 48 hours after injection of 211 MBq (5.7 mCi) In-111 octreotide showed an apparent increase in tracer uptake in the left chest posteriorly. This was not uniform in size or appearance. Tracer uptake elsewhere appeared physiologic. A previous computed tomographic (CT) scan revealed eventration of the left hemidiaphragm. The accumulation of In-111 octreotide in the patient's left chest posteriorly represents displaced abdominal contents, including the spleen, stomach, and bowel, as can be seen on the CT scan, and is considered to be physiologic in this case. This is a potential false-positive cause of In-111 octreotide uptake in the left chest, and a chest radiograph or CT should be reviewed in all patients with such an appearance.
- Published
- 2003
47. In-111 octreotide scintigraphy in adult medulloblastoma
- Author
-
P. Bello, I Hervás, Rosa Pérez-Velasco, and Antonio Mateo
- Subjects
Adult ,Male ,Cerebellum ,medicine.medical_specialty ,Adult Medulloblastoma ,Octreotide ,Computed tomographic ,Octreotide scintigraphy ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Cerebellar Neoplasms ,Radionuclide Imaging ,Medulloblastoma ,Epilepsy ,Somatostatin receptor scintigraphy ,business.industry ,Cancer ,General Medicine ,medicine.disease ,Cerebellar lesion ,Radiography ,medicine.anatomical_structure ,Radiology ,Neoplasm Recurrence, Local ,Radiopharmaceuticals ,business - Abstract
Medulloblastoma is a common cancer in children but not adults. The authors report the first case of adult medulloblastoma studied with somatostatin receptor scintigraphy (SRS). A 34-year-old man had a history of desmoplastic left cerebellar medulloblastoma that had been removed surgically. After surgery, findings of clinical follow-up and computed tomographic (CT) imaging were satisfactory. One month later, the patient had continuous epileptic seizures. CT scanning revealed nonspecific alterations after surgery in the left cerebellum. In-111 octreotide scintigraphy showed a left cerebellar lesion suggestive of residual tumor. In this case, conventional imaging did not detect the residual tumor that was clearly shown by SRS.
- Published
- 2003
48. Expression of somatostatin receptor types 2, 3 and 5 in biopsies and surgical specimens of human lung tumours. Correlation with preoperative octreotide scintigraphy
- Author
-
Elena Allia, Sabrina Croce, Marilena Bellò, Mauro Papotti, Marcus Schindler, Massimo Bongiovanni, and Gianni Bussolati
- Subjects
Adult ,Male ,endocrine system ,Pathology ,medicine.medical_specialty ,Lung Neoplasms ,Biopsy ,Octreotide ,Adenocarcinoma ,Scintigraphy ,Pathology and Forensic Medicine ,Immunoenzyme Techniques ,In vivo ,Preoperative Care ,medicine ,Carcinoma ,Humans ,RNA, Neoplasm ,Receptors, Somatostatin ,Radionuclide Imaging ,Molecular Biology ,Lung ,Tumors ,Aged ,DNA Primers ,medicine.diagnostic_test ,Somatostatin receptor ,business.industry ,Reverse Transcriptase Polymerase Chain Reaction ,Reproducibility of Results ,Somatostatin Receptors ,Cell Biology ,General Medicine ,Middle Aged ,medicine.disease ,Immunohistochemistry ,Octreotide Scintigraphy ,Somatostatin ,Female ,business ,hormones, hormone substitutes, and hormone antagonists ,medicine.drug - Abstract
The increasingly popular use of somatostatin analogs in clinical practice for both diagnostic and therapeutic purposes prompted extensive investigations on somatostatin receptor (sst) expression in human tumors by autoradiography, nucleic acid analysis and, recently, immunohistochemistry (IHC). The currently employed radiotracer for scintigraphy (Octreoscan) is octreotide, a somatostatin analog having a high affinity for sst types 2, 3, and 5. In this study on 25 patients, we compared sst 2, 3, and 5 expression in surgical and biopsy specimens of lung tumors, as revealed by immunohistochemical and reverse transcriptase polymerase chain reaction (RT-PCR), with the octreoscan outcome (which was positive in 20/25 cases). By IHC, the tumors mainly expressed sst2 (17/25, 68%) at the cell membrane level, while sst 3 and 5 were detected in a fraction of cases (24% and 20%, respectively). Comparing RT-PCR and IHC data, a correlation was found in 83.3% of cases, while octreoscan findings and sst expression were correlated in 22/25 cases (88%). In addition, cytological and biopsy specimens expressed the same sst type found in the corresponding surgical sample, thus indicating that a cell membrane sst immunoreactivity in a biopsy reliably predicts the tumor-receptor profile before its resection. Finally, sst expression was not restricted to neuroendocrine lung tumors, but was also a feature of some non-neuroendocrine carcinomas, although to a lesser extent. The occasional expression of sst subtypes in intratumoral lymphocytes, endothelia and necrotic areas is an additional feature to be considered in the interpretation of Octreoscan findings, since the in vivo procedure does not allow to define the sst cellular distribution. IHC can therefore be usefully coupled to radionuclear investigations to better characterize the sst cellular location and subtype in lung tumors.
- Published
- 2002
49. Ectopic ACTH-producing tumors of the chest and octreotide scintigraphy
- Author
-
Alberto Oliaro, Pier Luigi Filosso, Enrico Ruffini, and Ottavio Rena
- Subjects
Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,business.industry ,Ectopic acth ,Indium Radioisotopes ,General Medicine ,Thoracic Neoplasms ,ACTH Syndrome, Ectopic ,Neuroendocrine Tumors ,Adrenocorticotropic Hormone ,Octreotide scintigraphy ,Hormones, Ectopic ,Medicine ,Humans ,Surgery ,Radiology ,Radiopharmaceuticals ,Cardiology and Cardiovascular Medicine ,business ,Radionuclide Imaging ,Somatostatin - Published
- 2002
50. Cost comparison of 111In-DTPA-octreotide scintigraphy and 68Ga-DOTATOC PET/CT in Germany: two sides of two different coins
- Author
-
Juri Ruf
- Subjects
Male ,PET-CT ,medicine.medical_specialty ,Cost comparison ,business.industry ,General Medicine ,Pentetic Acid ,Octreotide ,Multimodal Imaging ,Pancreatic Neoplasms ,68ga dotatoc ,Neuroendocrine Tumors ,Positron-Emission Tomography ,Octreotide scintigraphy ,Organometallic Compounds ,Humans ,Medicine ,Female ,Radiology, Nuclear Medicine and imaging ,Radiology ,Tomography, X-Ray Computed ,business ,Nuclear medicine - Published
- 2011
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.